Cited by 1,047Atrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Open access

Siegal, Deborah M., Curnutte, John T., Connolly, Stuart J., Lu, Genmin, Conley, Pamela B., Wiens, Brian L., Mathur, Vandana S., Castillo, Janice, Bronson, Michele D., Leeds, Janet M., Mar, Florie A., Gold, Alex, Crowther, Mark A.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1510991

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors. METHODS: Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a measure of factor Xa inhibition by the anticoagulant. RESULTS: Among the apixaban-treated participants, anti-factor Xa activity was reduced by 94% among those who received an andexanet bolus (24 participants), as compared with 21% among those who received placebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per milliliter versus 1.9 ng per milliliter (P<0.001); thrombin generation was fully restored in 100% versus 11% of the participants (P<0.001) within 2 to 5 minutes. Among the rivaroxaban-treated participants, anti-factor Xa activity was reduced by 92% among those who received an andexanet bolus (27 participants), as compared with 18% among those who received placebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per milliliter versus 4.2 ng per milliliter (P<0.001); thrombin generation was fully restored in 96% versus 7% of the participants (P<0.001). These effects were sustained when andexanet was administered as a bolus plus an infusion. In a subgroup of participants, transient increases in levels of d-dimer and prothrombin fragments 1 and 2 were observed, which resolved within 24 to 72 hours. No serious adverse or thrombotic events were reported. CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and others; ANNEXA-A and ANNEXA-R ClinicalTrials.gov numbers, NCT02207725 and NCT02220725.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1510991

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,169
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K. Y., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 700
Self-citation
Probability Tables for Individual Comparisons by Ranking Methods
Wilcoxon, F. (1947) · Biometrics · doi:10.2307/3001946 · Cited by 578
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.958967 · Cited by 450
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Beyer‐Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C. U., Werth, S., Şahin, K., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563577 · Cited by 408
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 310

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 1

Crowther MA, 2013, J Thromb Haemost, 11, OC 20.1

Sorted by citations

Items 201–300 of 1,000

Direct oral anticoagulants in hypercoagulable states
Kunk, P. R., Brown, J. T., McShane, M., Palkimas, S., & Macik, B. G. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1420-x · Cited by 35
Management of Subdural Hematomas: Part II. Surgical Management of Subdural Hematomas
Fomchenko, E. I., Gilmore, E. J., Matouk, C. C., Gerrard, J. L., & Sheth, K. N. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0518-1 · Cited by 35
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage
Giovino, A., Shomo, E., Busey, K. V., Case, D., Brockhurst, A. C., & Concha, M. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.106070 · Cited by 35
Hemostasis in Intracranial Hemorrhage
Gulati, D., Dua, D., & Torbey, M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00080 · Cited by 36
Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines
Klaassen, Z. W. A., Arora, K., Goldberg, H., Chandrasekar, T., Wallis, C. J. D., Sayyid, R. K., Fleshner, N. E., Finelli, A., Kutikov, A., Violette, P. D., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.08.130 · Cited by 35
Antidote for Factor Xa Anticoagulants
Connors, J. M. (2015) · New England Journal of Medicine · doi:10.1056/nejme1513258 · Cited by 35
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial
Ezekowitz, M. D., Pollack, C. V., Sanders, P. W., Halperin, J. L., Spahr, J., Cater, N. B., Petkun, W., Breazna, A., Kirchhof, P. F., & Oldgren, J. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.008 · Cited by 34
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study
Dobesh, P. P., Fermann, G. J., Christoph, M. J., Koch, B., Lesén, E., Chen, H., Lovelace, B., Dettling, T., Danese, M. D., Ulloa, J., et al. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102192 · Cited by 34
The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
Wood, B., Nascimento, B., Rizoli, S. B., Sholzberg, M., McFarlan, A., Phillips, A., & Ackery, A. (2017) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/s13049-017-0420-y · Cited by 34
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 35
Self-citation
Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability
Siguret, V., Abdoul, J., Delavenne, X., Curis, E., Carlo, A., Blanchard, A., Salem, J., Gaussem, P., Funck‐Brentano, C., Azizi, M., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14541 · Cited by 34
Effect of Preinjury Oral Anticoagulants on Outcomes Following Traumatic Brain Injury from Falls in Older Adults
Hecht, J. P., LaDuke, Z. J., Cain‐Nielsen, A. H., Hemmila, M. R., & Wahl, W. L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2435 · Cited by 34
Discontinuation and management of direct-acting anticoagulants for emergency procedures
Levy, J. H. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.048 · Cited by 33
Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
Lu, G., Pine, P. R., Leeds, J. M., DeGuzman, F. R., Pratikhya, P., Lin, J. P., Malinowski, J., Hollenbach, S. J., Curnutte, J. T., & Conley, P. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195122 · Cited by 33
Self-citation
Heparin-Induced Thrombocytopenia in the Critically Ill Patient
East, J. M., Cserti-Gazdewich, C. M., & Granton, J. T. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.11.039 · Cited by 33
Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
Elhosseiny, S., Moussawi, H. A., Chalhoub, J. M., Lafferty, J., & Deeb, L. S. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/4383269 · Cited by 33
Pathogenesis, Diagnosis, and Treatment of Venous Thromboembolism in Older Adults
Johnson, S. A., Eleazer, G. P., & Rondina, M. T. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14279 · Cited by 32
Current status of oral anticoagulant reversal strategies: a review
Rawal, A., Ardeshna, D. R., Minhas, S., Cave, B. E., Ibeguogu, U., & Khouzam, R. N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.101 · Cited by 32
Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
Caturano, A., Galiero, R., & Pafundi, P. C. (2019) · Medicina · doi:10.3390/medicina55100617 · Cited by 32
Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents
Kaide, C. G., & Gulseth, M. P. (2019) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.10.011 · Cited by 33
Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review
Hsu, J. C., & Freeman, J. V. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1024 · Cited by 32
Reducing risk of spinal haematoma from spinal and epidural pain procedures
Breivik, H., Norum, H. M., Eriksen, C. F., Alahuhta, S., Vigfússon, G., Thomas, O. D., & Lagerkranser, M. (2018) · Scandinavian Journal of Pain · doi:10.1515/sjpain-2018-0041 · Cited by 32
Bleeding associated with coadministration of rivaroxaban and clarithromycin
Fralick, M., Juurlink, D. N., & Marras, T. K. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.150580 · Cited by 31
Management of bleeding in patients treated with direct oral anticoagulants
Levi, M. M. (2016) · Critical Care · doi:10.1186/s13054-016-1413-3 · Cited by 31
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants
Kaatz, S. S., Mahan, C. E., Nakhle, A., Gunasekaran, K., Ali, M., Lavender, R. C., & Paje, D. G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0930-2 · Cited by 31
Direct oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 31
Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis
Levy, J. H., Connors, J. M., Steiner, M. E., Douketis, J. D., & Spyropoulos, A. C. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12320 · Cited by 31
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding
Cao, D., Amabile, N., Chiarito, M., Lee, V. T., Angiolillo, D. J., Capodanno, D., Bhatt, D. L., Mack, M. J., Storey, R. F., Schmoeckel, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad119 · Cited by 31
Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Mulligan, S. P., Wård, C., Whalley, D. W., & Hilmer, S. N. (2016) · British Journal of Haematology · doi:10.1111/bjh.14321 · Cited by 30
Preclinical and clinical data for factor Xa and “universal” reversal agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.052 · Cited by 31
Reversal of direct oral anticoagulants
Almegren, M. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s138890 · Cited by 30
Andexanet alfa—The first 150 days
Culbreth, S. E., Rimsans, J., Sylvester, K. W., Pallin, D. J., & Connors, J. M. (2018) · American Journal of Hematology · doi:10.1002/ajh.25326 · Cited by 30
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation
Sin, J. H., Berger, K., & Lesch, C. A. (2016) · Journal of Critical Care · doi:10.1016/j.jcrc.2016.06.024 · Cited by 30
Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
Siddiqui, F., Hoppensteadt, D., Jeske, W. P., Iqbal, O., Tafur, A. J., & Fareed, J. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619847524 · Cited by 30
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA)
Rogers, K. C., & Finks, S. W. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.06.028 · Cited by 29
Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists
Desai, N. R., & Cornutt, D. (2019) · Hospital Practice · doi:10.1080/21548331.2019.1643728 · Cited by 29
Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
Watson, C. J., Zettervall, S. L., Hall, M. J., & Ganetsky, M. (2019) · Clinical Practice and Cases in Emergency Medicine · doi:10.5811/cpcem.2019.9.43650 · Cited by 29
Management of cardiovascular complications of bruton tyrosine kinase inhibitors
Tang, C. P. S., Lip, G. Y. H., McCormack, T., Lyon, A. R., Hillmen, P., Iyengar, S., Martínez‐Calle, N., Parry‐Jones, N., Patten, P., Schuh, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17788 · Cited by 29
Andexxa—An Antidote for Apixaban and Rivaroxaban
(2018) · JAMA · doi:10.1001/jama.2018.9257 · Cited by 29
Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy
Oprea, A. D., Noto, C. J., & Halaszynski, T. M. (2016) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2016.06.016 · Cited by 29
A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism
Comerota, A. J., & Ramacciotti, E. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.03.018 · Cited by 28
Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Rességuier, A.-S., Pereira, B., Rieu, V., Guenno, G. L., Grobost, V., & Ruivard, M. (2017) · Lupus · doi:10.1177/0961203317701841 · Cited by 28
Pharmacogenetics of Novel Oral Anticoagulants: A Review of Identified Gene Variants & Future Perspectives
Ašić, A., Marjanović, D., Mirat, J., & Primorac, D. (2018) · Personalized Medicine · doi:10.2217/pme-2017-0092 · Cited by 28
Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series
Smetana, K. S., Dunne, J., Parrott, K., Davis, G. A., Collier, A. C. S., Covell, M. B., & Smyth, S. S. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1560-7 · Cited by 27
Advances in Stroke 2017
Bernhardt, J. A., Zorowitz, R. D., Becker, K. J., Keller, E., Saposnik, G., Strbian, D., Dichgans, M., Woo, D., Reeves, M. J., Thrift, A. G., et al. (2018) · Stroke · doi:10.1161/strokeaha.118.021380 · Cited by 27
Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications
Dabi, A., & Koutrouvelis, A. P. (2018) · Critical Care Research and Practice · doi:10.1155/2018/4907164 · Cited by 27
Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants.
Momin, J. H., Candidate, P., & Hughes, G. J. (2019) · PubMed Central · Cited by 27
Pull back the curtain: External data validation is an essential element of quality improvement benchmark reporting
Jakubus, J. L., Pasquo, S. L. D., Mikhail, J. N., Cain‐Nielsen, A. H., Jenkins, P. C., & Hemmila, M. R. (2020) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002579 · Cited by 27
Emergency management of intracerebral hemorrhage
Mazzoleni, V., Padovani, A., & Morotti, A. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2022.154232 · Cited by 27
Transanal hemorrhoidal dearterialization (THD): a safe procedure for the anticoagulated patient?
Atallah, S. B., Maharaja, G., Martín-Pérez, B., Burke, J. P., Albert, M. R., & Larach, S. W. (2016) · Techniques in Coloproctology · doi:10.1007/s10151-016-1481-z · Cited by 27
Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants
Trikha, R., & Kowey, P. R. (2016) · Cardiology · doi:10.1159/000447530 · Cited by 27
Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay
Schenk, B., Würtinger, P., Streif, W., Sturm, W., Fries, D. R., & Bachler, M. (2016) · British Journal of Anaesthesia · doi:10.1093/bja/aew259 · Cited by 27
Bleeding with direct oral anticoagulants vs warfarin: clinical experience
Eikelboom, J. W., & Merli, G. J. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.046 · Cited by 27
Point-of-Care Coagulation Tests Monitoring of Direct Oral Anticoagulants and Their Reversal Therapy: State of the Art
Bianchi, P. A., Ranucci, M., Baryshnikova, E., & Iapichino, G. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1599157 · Cited by 27
Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis
Keshari, R. S., Silasi‐Mansat, R., Popescu, N. I., Georgescu, C., Chaaban, H., Lupu, C., McCarty, O. J. T., Esmon, C. T., & Lupu, F. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14642 · Cited by 27
Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio
Bernier, M., Lancrerot, S.-L., Parassol, N., Lavrut, T., Viotti, J., Rocher, F., & Drici, M. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000870 · Cited by 27
Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020
Alkhezi, O. S., Buckley, L. F., & Fanikos, J. R. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00638-4 · Cited by 27
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro
McCullough, P. A., Ball, T. N., Cox, K. M., & Assar, M. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02680316 · Cited by 26
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
Schenk, B., Goerke, S., Beer, R., Helbok, R., Fries, D. R., & Bachler, M. (2018) · Thrombosis Journal · doi:10.1186/s12959-017-0158-9 · Cited by 26
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 30
Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
Nederpelt, C. J., Naar, L., Sylvester, K. W., Barra, M. E., Roberts, R. J., Velmahos, G. C., Kaafarani, H. M. A., Rosenthal, M. G., & King, D. R. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15031 · Cited by 26
Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics
Thompson, L. E., Davis, B. H., Narayan, R., Goff, B., Brown, T. M., & Limdi, N. A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2714 · Cited by 27
Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice
Aldhaeefi, M., Badreldin, H. A., Alsuwayyid, F., Alqahtani, T., Alshaya, O. A., Yami, M. S. A., Saleh, K. B., Harbi, S. A. A., & Alshaya, A. I. (2023) · Pharmacy · doi:10.3390/pharmacy11010034 · Cited by 26
Approaches to prevent bleeding associated with anticoagulants: current status and recent developments
Kalathottukaren, M. T., Haynes, C. A., & Kizhakkedathu, J. N. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0413-4 · Cited by 26
Preoperative cardiac assessment in liver transplant candidates
GASPERI, A. D., Spagnolin, G., Ornaghi, M., Petrò, L., & Biancofiore, G. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.02.002 · Cited by 26
Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants
Weitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 25
New Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 25
A Review of the Efficacy and Safety Profiles of the Novel Oral Anticoagulants in the Treatment and Prevention of Venous Thromboembolism
Coulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 25
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations
Undas, A., Drabik, L., & Potpara, T. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15136 · Cited by 25
The APB study: apixaban pharmacokinetics in bariatric patients before to 1 year after vertical sleeve gastrectomy or Roux-en-Y gastric bypass
Steele, K. E., Prokopowicz, G. P., Canner, J., Harris, C., Jurao, R. A., Kickler, T. S., Streiff, M. B., & Petty, B. G. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.12.023 · Cited by 25
A systematic review of anti-thrombotic therapy in epistaxis
Musgrave, K. M., & Powell, J. (2016) · Rhinology Journal · doi:10.4193/rhin16.040 · Cited by 25
Perioperative management of oral anticoagulation
McIlmoyle, K., & Tran, H. A. (2018) · BJA Education · doi:10.1016/j.bjae.2018.05.007 · Cited by 25
The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA)
Favaloro, E. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25606 · Cited by 25
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis
Milling, T. J., Clark, C. L., Feronti, C. J., Song, S. S., Torbati, S. S., Fermann, G. J., Weiss, J., & Patel, D. (2017) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2017.08.042 · Cited by 25
North American Thrombosis Forum, AF Action Initiative Consensus Document
Ruff, C. T., Ansell, J., Becker, R. C., Benjamin, E. J., Deicicchi, D. J., Estes, N. A. M., Ezekowitz, M. D., Fanikos, J. R., Fareed, J., Garcia, D. A., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.001 · Cited by 24
Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors
Xing, J., Yang, L., Yang, Y. K., Zhao, L., Wei, Q., Zhang, J., Zhou, J., & Zhang, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.055 · Cited by 24
Major publications in the critical care pharmacotherapy literature in 2015
Wong, A., Erdman, M. J., Hammond, D. A., Holt, T., Holzhausen, J. M., Horng, M., Huang, L. L., Jarvis, J., Kram, B., Kram, S. J., et al. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160144 · Cited by 24
Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies
Lobraico-Fernandez, J., Baksh, S., & Nemec, E. C. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0275-y · Cited by 24
Andexanet Alfa (Andexxa) Formulary Review
Beik, N., Reddy, P., Sylvester, K. W., Connell, N. T., Giugliano, R. P., Piazza, G., & Connors, J. M. (2019) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000177 · Cited by 24
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.009 · Cited by 25
Electrophysiology and heart rhythm disorders in older adults.
Goyal, P., & Rich, M. W. (2016) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2016.08.001 · Cited by 23
Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage
Sembill, J. A., Huttner, H. B., & Kuramatsu, J. B. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0872-0 · Cited by 23
What we have learned about direct oral anticoagulant reversal
Siegal, D. M. (2019) · Hematology · doi:10.1182/hematology.2019000072 · Cited by 23
Self-citation
Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
Bourdin, M., Perrotin, D., Mathieu, O., Herve, T., Depasse, F., Lu, G., Conley, P. B., & Contant, G. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13591 · Cited by 23
Self-citation
Global access to affordable direct oral anticoagulants
Neumann, I., Schünemann, H. J., Bero, L., Cooke, G., Magrini, N., & Moja, L. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.278473 · Cited by 23
Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage
Lipski, M., Pasciolla, S., Wojcik, K., Jankowitz, B. T., & Igneri, L. A. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02752-z · Cited by 23
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures
Levy, J. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.005 · Cited by 23
Coagulopathy Before and After Liver Transplantation
Stine, J. G., & Northup, P. G. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.12.003 · Cited by 23
Direct oral anticoagulants (DOAC) – Management of emergency situations
Lindhoff‐Last, E. (2017) · Hämostaseologie · doi:10.5482/hamo-16-11-0043 · Cited by 23
Antithrombotics in trauma: management strategies in the older patients
Wong, H., Lovett, N. G., Curry, N. S., Shah, K., & Stanworth, S. J. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s125209 · Cited by 23
European guidelines on perioperative venous thromboembolism prophylaxis
Ahmed, A. B., Kozek‐Langenecker, S. A., Mullier, F., Pavord, S. R., & Hermans, C. R. J. R. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000725 · Cited by 23
Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation
Martin, A., Godiér, A., Narayanan, K., Smadja, D. M., & Marijon, É. (2018) · Circulation · doi:10.1161/circulationaha.117.033326 · Cited by 23
Management of Severe Bleeding in Patients Treated With Oral Anticoagulants
Gibler, W. B., Racadio, J. M., Hirsch, A. L., & Roat, T. W. (2019) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000181 · Cited by 23
Association of mortality among trauma patients taking preinjury direct oral anticoagulants versus vitamin K antagonists
LaDuke, Z. J., Hecht, J. P., Cain‐Nielsen, A. H., Hemmila, M. R., & Wahl, W. L. (2019) · Surgery · doi:10.1016/j.surg.2019.04.039 · Cited by 23
Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding
Korobey, M. J., Sadaka, F. G., Javed, M. A., Moynihan, M., & Alsaei, A. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00968-6 · Cited by 23
Management of Venous Thromboembolism
Finks, S. W., Trujillo, T. C., & Dobesh, P. P. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016632785 · Cited by 22
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
Brown, K. S., Zahir, H., GROSSO, M. A., Lanz, H., Mercuri, M. F., & Levy, J. H. (2016) · Critical Care · doi:10.1186/s13054-016-1422-2 · Cited by 22
Intracerebral Hemorrhage Formation Under Direct Oral Anticoagulants
Foerch, C., Lo, E. H., van Leyen, K., Lauer, A., & Schäefer, J. H. (2019) · Stroke · doi:10.1161/strokeaha.118.023722 · Cited by 22
Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing
Sommerauer, C., Schlender, L., Krause, M., Weißbach, S., Rieckert, A., Martinez, Y. V., Reeves, D., Guiteras, A. R., Kunnamo, I., & Sönnichsen, A. C. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0573-6 · Cited by 22
Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
Pundi, K. N., Perino, A. C., Fan, J., Schmitt, S. K., Kothari, M., Szummer, K. E., Askari, M., Heidenreich, P. A., & Turakhia, M. P. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020904 · Cited by 22

Authors: Siegal, D. M., Curnutte, J. T., Connolly, S. J., Lu, G., Conley, P. B., Wiens, B. L., Mathur, V. S., Castillo, J., Bronson, M. D., Leeds, J. M., Mar, F. A., Gold, A., & Crowther, M. A.
Affiliations: Population Health Research Institute (CA)
Portola Pharmaceuticals (United States) (US)
McMaster University (CA)
ORCID: Siegal, Deborah M.
Connolly, Stuart J.
Lu, Genmin
Conley, Pamela B.
Wiens, Brian L.
Mathur, Vandana S.
Crowther, Mark A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-12-17
Volume: 373
Issue: 25
Pages: 2413-2424
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1510991
OpenAlex: W2174386486
Cited by: 1,047
References: 22
Citations by year: 2026: 21 · 2025: 34 · 2024: 48 · 2023: 56 · 2022: 44 · 2021: 57 · 2020: 91 · 2019: 126 · 2018: 133 · 2017: 175 · 2016: 249 · 2015: 11
FWCI: 137.31
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: andexanet alfa, factor Xa inhibitors, apixaban, rivaroxaban, anticoagulant reversal, bleeding complications, anti-Xa activity, thrombin generation, unbound drug concentration, D-dimer, prothrombin fragments, older adults, drug safety, pharmacokinetics, pharmacodynamics, thromboprophylaxis, thrombolysis
MeSH terms: Rivaroxaban, Administration, Oral, Aged, Antidotes, Blood Coagulation, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Peptide Fragments, Protein Precursors, Prothrombin, Pyrazoles, Pyridones, Recombinant Proteins, Factor Xa, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks